KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) Other Operating Expenses (2017 - 2025)

Historic Other Operating Expenses for Moderna (MRNA) over the last 8 years, with Q3 2025 value amounting to $207.0 million.

  • Moderna's Other Operating Expenses fell 5972.76% to $207.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year decrease of 3016.93%. This contributed to the annual value of $1.5 billion for FY2024, which is 6880.46% down from last year.
  • Latest data reveals that Moderna reported Other Operating Expenses of $207.0 million as of Q3 2025, which was down 5972.76% from $119.0 million recorded in Q2 2025.
  • Moderna's Other Operating Expenses' 5-year high stood at $2.2 billion during Q3 2023, with a 5-year trough of $90.0 million in Q1 2025.
  • Its 5-year average for Other Operating Expenses is $768.7 million, with a median of $739.0 million in 2024.
  • Per our database at Business Quant, Moderna's Other Operating Expenses soared by 1180000.0% in 2021 and then plummeted by 8787.88% in 2024.
  • Over the past 5 years, Moderna's Other Operating Expenses (Quarter) stood at $952.0 million in 2021, then surged by 101.47% to $1.9 billion in 2022, then crashed by 51.56% to $929.0 million in 2023, then dropped by 20.45% to $739.0 million in 2024, then plummeted by 71.99% to $207.0 million in 2025.
  • Its Other Operating Expenses stands at $207.0 million for Q3 2025, versus $119.0 million for Q2 2025 and $90.0 million for Q1 2025.